



Neuren Pharmaceuticals Ltd  
Level 1, 103 Carlton Gore Road  
Newmarket, Auckland, New Zealand  
office: +64 9 529 3940  
fax: +64 9 529 3941  
enquiries@neurenpharma.com  
www.neurenpharma.com

<name>  
<address>  
<address>  
<address>  
<address>  
<address>

20 December 2007

Dear Shareholder

**Neuren Pharmaceuticals Limited – Non-renounceable Rights Issue**

On 19 December 2007 Neuren Pharmaceuticals Limited (“Neuren”) announced on ASX Limited a 1 for 2 non-renounceable rights issue (“Rights Issue”) of ordinary shares at A\$0.14 per New Share (or NZ\$0.16 per New Share for New Zealand resident shareholders) would be offered to Australian and New Zealand resident shareholders recorded on the share register on 2 January 2008 (“Record Date”). A copy of this announcement is available on the ASX website [www.asx.com.au](http://www.asx.com.au) or from Neuren’s website [www.neurenpharma.com](http://www.neurenpharma.com).

In accordance with Listing Rule 7.7.1 of the ASX, the Company has considered the number of shareholders with registered addresses outside of Australia and New Zealand and the size of the shareholdings held by those shareholders. Taking this into consideration as well as the costs of complying with the legal requirements and the requirements of the regulatory authorities relating to shareholders with registered addresses outside of Australia and New Zealand, Neuren has formed the view that it is unreasonable to extend the Rights Issue to those shareholders.

Accordingly, Neuren is unable to extend to you the opportunity to participate in the Rights Issue.

If you have any questions in relation to the Rights Issue, please do not hesitate to contact Neuren on +64 (9) 529 3940 or by email to [enquiries@neurenpharma.com](mailto:enquiries@neurenpharma.com).

Yours sincerely

A handwritten signature in black ink, appearing to read "Rob Turnbull".

Mr Rob Turnbull  
Chief Financial Officer